Anti-human CD22/Siglec 2 Monoclonal Antibody FITC Conjugated, Flow Validated

CD22 or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. This gene is mapped to 19q13.2. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases. It is a negative regulator of antigen receptor signaling whose onset of expression at the mature B cell stage may serve to raise the antigen concentration threshold required for B cell triggering. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signalling. This gene can downmodulate signaling through the IgM and IgD B-cell receptors (BCRs), but not through the IgG BCR, because the IgG cytoplasmic tail prevents CD22 phosphorylation and actually enhances IgG-BCR signaling.

B-cell receptor CD22; B-lymphocyte cell adhesion molecule; BL-CAM; Sialic acid-binding Ig-like lectin 2; Siglec-2; T-cell surface antigen Leu-14; CD22; CD22; SIGLEC2

Adaptive Immunity, B Cells, Cancer, Hematopoietic Progenitors, Immunology, Lymphoid, Stem Cells, Tumor Antigens, Tumor Biomarkers, Tumor Immunology, Tumor-Associated Antigens

Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.